 IRVINE, Calif., Dec. 21, 2020 GLOBE NEWSWIRE -- Tarsus Pharmaceuticals, Inc. NASDAQ: TARS, a late clinical-stage biopharmaceutical company whose mission is to discover and deliver breakthrough treatments to transform the lives of patients with common and poorly treated diseases, starting with the eye, today announced that it has been added to the broad-market Russell 3000 Index and the small-cap Russell 2000 Index as part of the indexs quarterly initial public offering IPO additions. 